Wednesday, June 10, 2026

pharma · Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · IgA Nephropathy (IgAN) · VERA

Vera Therapeutics

VERALOX Therapeutics is a pharma organization headquartered in Frederick, USA. It trades on NYSE under ticker VERA. Primary therapeutic focus areas include Recurrent Low-Grade Serous Ovarian Cancer (LGSOC), IgA Nephropat

4539 Metropolitan Ct, Frederick, Maryland 21704, US HQ
2018 Founded
9 Employees
Public company Type
VERA · NYSE Ticker
Company details
Status
Public
HQ
4539 Metropolitan Ct, Frederick, Maryland 21704, US
Founded
2018
Employees
9
Programs
25
Drugs
32
Patents
140

Quick answer

VERALOX Therapeutics is a pharma organization headquartered in Frederick, USA. It trades on NYSE under ticker VERA. Primary therapeutic focus areas include Recurrent Low-Grade Serous Ovarian Cancer (LGSOC), IgA Nephropathy (IgAN), HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study, Coronary Artery Disease, Hepatitis B, Chronic. NovaPharmaNews links 25 clinical program(s), 2 drug profile(s), and 140 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (13), phase 3 (4), approved (4).

Company snapshot

Accelerating development of first-in-class therapeutics for unmet medical needs

  • 2 approved product(s) across US/EU regulatory metadata.
  • 25 active pipeline program(s) linked via ClinicalTrials.gov.
  • 140 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Vera Therapeutics. Not investment advice.

Catalysts

Upcoming readouts, regulatory dates, and congress activity.

  • trial_data

    New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights

Recent coverage

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Vera Therapeutics.

2 active signals

24 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 19 30d
  • Nova articles 1 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Recent activity

Latest pipeline, patent, and corporate events for Vera Therapeutics.

  1. Clinical update

    VS-6766-301 — Phase 3

  2. Clinical update

    Remifentanil — Unknown

  3. Clinical update

    Pregabalin — Approved

  4. Clinical update

    Peginterferon alfa-2a — Approved

  5. Clinical update

    P2Y12 antagonist monotherapy — Unknown

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Vera Therapeutics?

    VERALOX Therapeutics is a pharma organization headquartered in Frederick, USA. It trades on NYSE under ticker VERA. Primary therapeutic focus areas include Recurrent Low-Grade Serous Ovarian Cancer (LGSOC), IgA Nephropathy (IgAN), HER2 Enriched Subtype Breast Cancer, Herzuma, PAM

  • Is Vera Therapeutics publicly traded?

    Yes. Vera Therapeutics is listed with ticker VERA on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does Vera Therapeutics develop or market?

    We link 32 drug profile(s) where Vera Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/vera-therapeutics#company-drugs.

  • What are the latest developments for Vera Therapeutics?

    In the last 12 months our linked public records show 25 trial program update(s) and 5 US patent grant(s) tied to this profile.

  • What therapeutic areas does Vera Therapeutics focus on?

    Vera Therapeutics focuses on Recurrent Low-Grade Serous Ovarian Cancer (LGSOC), IgA Nephropathy (IgAN), HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
27
Oncology
7
Infectious Disease
5
Immunology
5
Neurology
1